Previous Article | Next Article 
Infection and Immunity, August 2001, p. 4988-4995, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.4988-4995.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Reciprocal, Temporal Expression of SpeA and SpeB by
Invasive M1T1 Group A Streptococcal Isolates In Vivo
Shahana U.
Kazmi,1,2
Rita
Kansal,1,2
Ramy K.
Aziz,1,2
Massoumeh
Hooshdaran,1,2
Anna
Norrby-Teglund,3
D. E.
Low,4
Abdel-Baset
Halim,1,2 and
Malak
Kotb1,2,*
Research Service, Veterans Affairs Medical Center,
Memphis, Tennessee 381041; Departments
of Surgery and of Microbiology and Immunology, University of
Tennessee, Memphis, Memphis, Tennessee 381632;
Karolinska Institute Huddinge University Hospital, SE-141
86 Huddinge, Sweden3; and Mount Sinai
Hospital, Toronto, Ontario, Canada M5G 1X54
Received 9 January 2001/Returned for modification 27 March
2001/Accepted 4 May 2001
 |
ABSTRACT |
The streptococcal pyrogenic exotoxins (Spes) play a central role in
the pathogenesis of invasive group A streptococcal (GAS) infections.
The majority of recent invasive GAS infections have been caused by an
M1T1 strain that harbors the genes for several streptococcal
superantigens, including speA, speB,
speF, speG, and smeZ.
However, considerable variation in the expression of Spe proteins among
clonal M1 isolates has been found, and many of the
speA-positive M1 strains do not produce detectable
amounts of SpeA in vitro. This study was designed to test the
hypothesis that speA gene expression can be induced in
vivo. A mouse infection chamber model that allows sequential sampling
of GAS isolates at various time points postinfection was developed and
used to monitor the kinetics of Spe production in vivo. Micropore
Teflon diffusion chambers were implanted subcutaneously in BALB/c mice, and after 3 weeks the pores became sealed with connective tissue and
sterile fluid containing a white blood cell infiltrate
accumulated inside the infection chambers. Representative clonal M1T1
isolates expressing no detectable SpeA were inoculated into the
implanted chambers, and the expression of SpeA in the aspirated
aliquots of the chamber fluid was analyzed on successive days
postinfection. Expression of SpeA was detected in the chamber fluid as
early as days 3 to 5 postinfection in most animals, with a significant increase in expression by day 7 in all infected mice. Isolates recovered from the chamber and grown in vitro continued to produce SpeA
even after 21 passages in vitro, suggesting stable switch on of the
speA gene. A temporal relation between the upregulation of SpeA expression and the downregulation of SpeB expression was observed in vivo. These data suggest that in vivo host and/or environmental signals induced speA gene expression and
suppressed speB gene expression. This underscores the
role of the host-pathogen interaction in regulating the expression of
streptococcal virulence factors in vivo. The model described here
should facilitate such studies.
 |
INTRODUCTION |
Group A streptococci (GAS)
are important human pathogens capable of causing a wide variety of
infections ranging from simple nasopharyngitis to highly invasive and
fatal infections such as necrotizing fasciitis and streptococcal toxic
shock syndrome (STSS). GAS have a vast repertoire of virulence factors
that participate in pathogenesis (reviewed in references 13, 15,
and 38). The streptococcal pyrogenic exotoxins (Spes) are
superantigens that induce potent inflammatory responses and cause
tissue damage (19, 48) and play a major role in the
pathogenesis of STSS (19). Expression of many of the GAS
virulence factors can vary considerably among the different GAS strains
as well as within clinical isolates of the same clonal strain
(7). The mechanism by which expression of these virulence
factors is regulated and the impact of variable expression of GAS
virulence factors on pathogenesis are currently intense areas of
investigation in many laboratories (1, 2, 4, 14, 16, 22, 23, 25, 30, 32, 40-42). However, despite the central role of the other Spe superantigens such as SpeA in the pathogenesis of invasive GAS
infections (19, 20, 38), little is known about the
regulation of its expression in vitro or in vivo.
The majority of recent invasive GAS infections have been caused by a
clonal M1T1 strain that has the speA, speB,
speF, speG, and smeZ genes (7,
11, 28; A. McGeer, K. Green, D. Cann, B. Schwartz, R. Kaul, A. Fletcher, S. Matsumura, the Ontario Group A Streptococcal Study Group,
and D. E. Low, Abstr. 35th Intersci. Conf. Antimicrob. Agents
Chemother., abstr. K135, 1995). However, a recent study by Chatellier
et al. (7) noted highly variable expression of Spes among
clonal M1T1 isolates from invasive infection cases. In particular, the
expression of SpeA was either very low or undetectable in 40% of the
isolates (7), and an inverse relation between SpeB
expression and disease severity was found (18). Variable
expression of SpeA among speA-positive isolates has also
been noted by several investigators, who observed that only 20 to 50%
of the speA-positive M1 isolates they studied expressed SpeA
(9, 17, 34, 47).
The failure of some M1 speA-positive isolates to express
detectable amounts of SpeA protein while other M1 isolates derived from
the same clone express constitutive high levels of SpeA remains unexplained. Further, the biological relevance of this phenomenon is
unclear. In an attempt to address these issues we investigated whether
speA gene expression can be induced in vitro under various growth conditions or in vivo in a mouse model that we have developed. Here we report that SpeA expression was stably turned on in vivo, and a
reciprocal temporal relation between SpeA and SpeB expression was observed. The data support the hypothesis that host factors may
play an important role in regulating the expression of GAS virulence
genes and underscore the role of host-pathogen interactions in GAS pathogenesis.
 |
MATERIALS AND METHODS |
Bacterial strains.
Seven representative M1T1
speA-positive strains of Streptococcus pyogenes
were isolated from patients with STSS cases that were recruited from
December 1994 to July 1996 through an ongoing population-based
surveillance for invasive GAS infections in Ontario, Canada. All
strains were determined to be derived from the same clone as detailed
elsewhere (7). Original isolates recovered from patients
were grown once to avoid in vitro passage, aliquoted, and stored
frozen. The serotype of the M1 strains used here was confirmed by
sequencing the emm gene, and the presence of Spe genes was
determined by PCR as previously described (7). All M1T1
strains had the emm1.1, speA.2, speB,
speF, speG, and smeZ genes. With the
exception of isolate 8004, none of the isolates selected for this study
expressed the SpeA protein. Therefore, isolate 8004 served as positive
control, and M49 isolate NZ131, which lacks the speA gene,
served as a negative control for speA expression. Isolates
5459, 5628, and 8004 did not express SpeB.
Animals.
Female 6- to 8-week-old BALB/c mice weighing 22 to
25 g were obtained from Jackson Laboratories (Bar Harbor, Maine).
The mice were housed on hardwood chip bedding in microisolator cages in a room kept at 23°C with 50 to 60% relative humidity and a 12-h light-dark cycle and were given tap water and sterile irradiated rodent
chow (Rodent Chow 2001; Ralston Purina, St. Louis, Mo.) ad libitum. The
mice were housed five per cage, were randomly assigned to treatment or
control groups, and were allowed to acclimate to the laboratory
environment for a minimum of 10 days before being prepared for surgery.
All protocols involving animals were approved by the Institutional
Animal Care and use Committee of The University of Tennessee, Memphis.
Implantation of tissue chambers.
Autoclaved sterile
Teflon-FEP (Fisher, Suwanee, Ga.) tissue chambers, which were 20 by 10 mm and perforated by 110 equally spaced 1-mm-diameter
holes with two larger holes at both ends to allow penetrance of
a 27-gauge needle, were manufactured in our Biomedical Instrumentation
Department (University of Tennessee, Memphis) (Fig.
1). The sterile tissue chambers were
implanted under aseptic conditions through a small incision in the
subcutaneous connective tissue in the backsides of 6- to 8-week-old
BALB/c mice. The incisions were closed with 9-mm wound clips,
and a Betadine-iodine solution was sprayed over the wound to avoid
infection. After inoculation of the bacteria into the implanted
chambers, each mouse was housed in a separate cage and all were fed
sterilized chow. The chambers were checked for sterility 3 weeks after
implantation by culturing 100-µl aliquots of chamber fluid on sheep
blood agar plates (Difco, Detroit, Mich.) for 24 h at 37°C.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 1.
Tissue chamber used in localized infection model.
Teflon-FEP tissue chambers (20 by 10 mm) were perforated by 110 equally
spaced 1-mm-diameter holes with a larger hole at one end to
allow penetration of a 25-gauge needle. The chambers were implanted
through a small incision in the subcutaneous connective tissue of the
backsides of mice. After 3 weeks, the pores were sealed with
vascularized connective tissue and the chamber was filled with a
straw-colored sterile fluid.
|
|
Effect of environmental conditions on the expression of SpeA in
vitro.
GAS isolates recovered from sterile sites of patients with
invasive disease were streaked on blood agar plates. After overnight incubation, three pure colonies were picked and cultured overnight in
10 ml of standard medium (i.e., Todd-Hewitt broth plus 1.5% yeast
extract). In some experiments, GAS isolates were cultured under
different environmental conditions that included (i) incubation at
different temperatures (25, 30, 37, or 42°C); (ii) culturing in broth
supplemented with riboflavin (2 mg/ml), ferric citrate (13 mM), or the
iron-chelating agents ethylenediaminediacetic acid (18 mM) and/or
nitrilotriacetic acid (18 mM) alone or in combination with
ferric citrate; and (iii) incubation under static or shaking
conditions. In addition, GAS cultures were incubated in ambient air or
in the presence of 5 and 10% CO2. Variation in
CO2 content was made possible by using a
commercial gas generator (Campy GasPac; BBL).
Partially purified bacterial culture supernatants were prepared by
ethanol precipitation as detailed elsewhere (18). In some
experiments the bacteria were grown in the presence of cysteine protease inhibitor E-64 (28 µM) to block SpeB proteolytic activity. Complete inhibition of cysteine protease activity by E-64 was confirmed
using the EnzChek protease assay kit (Molecular Probes Inc., Eugene,
Oreg.) as previously described (18).
Preparation of bacterial inoculum.
To prepare the bacteria
for in vivo inoculation into mice, pure colonies were isolated and
cultured overnight at 37°C in standard media under static conditions.
The number of CFU per milliliter was determined, and, depending on the
experiment, 1 × 103 to 5 × 105 CFU were inoculated into each tissue chamber.
Isolate supernatants prepared immediately prior to infection were
designated day 0 supernatants, and these were analyzed for Spe
expression by Western blotting as described below.
Animal infection.
Infection of the sealed, implanted tissue
chambers was done 3 weeks postimplantation. On day 0 of infection, 100 µl of the chamber fluid was aspirated from each chamber and cultured
for a sterility check. Each chamber in the test group was inoculated with 100 µl containing 1 × 105 to 5 × 105 CFU of the GAS strain tested
diluted in phosphate-buffered saline (PBS). Control animals received
the same volume of endotoxin-free PBS (Gibco). Sequential aspiration of
tissue chamber fluid was done on specified days after inoculation; the
fluid was from the same mouse or in some cases from different
mice designated for sampling on different days. The progress of
infection inside the chamber was monitored by determining the
number of CFU in 100 µl of chamber fluid aspirated from the
chambers on different days.
The chamber fluid recovered on various days was centrifuged to remove
cells, bacteria, and debris prior to Western blot analysis for SpeA,
SpeB, and SpeF expression, as described below. Bacteria recovered from
the chambers on different days were grown in vitro for up to 21 passages, and the partially purified supernatants from the bacterial
cultures of each passage were also analyzed in Western blots for Spe
production as described below.
In some experiments mice were sacrificed on different days
postinfection to observe gross morphological changes in liver, heart,
spleen, and kidney. Blood samples, peritoneal fluid, and several
organs, including spleen, lung, liver, and kidney, were processed for
determination of CFU per milliliter to investigate the systemic spread
of infection.
Detection of SpeA, SpeB, and SpeF by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and immunoblotting.
Expression of Spe proteins in bacterial culture supernatants or in the
fluid recovered from the chambers was detected by Western blotting as
described previously (7, 18) using rabbit polyclonal antibodies raised against recombinant SpeA (rSpeA) or rSpeF, both of
which were generated as previously reported (3), or an
anti-SpeB mouse monoclonal antiserum, which was a gift from James
Musser (National Institute of Allergy and Infectious Diseases,
Hamilton, Mont.). Spe expression was detected by the
luminol-chemiluminescence reagents (ECL; Amersham Life Sciences Ltd.,
Buckinghamshire, England). The processed blots were exposed to X-ray
films, and the autoradiograms were analyzed.
Colony lift immunoblot assay.
Original isolates or isolates
recovered from the chambers on the various days postinfection were
diluted (103- to 106-fold)
and plated on blood agar plates. Colonies were overlaid with a
nitrocellulose membrane disk and incubated to allow the binding of
secreted proteins. SpeA was detected by probing the membranes with
anti-rSpeA rabbit antisera (at 1:2,000 dilution) followed by goat
anti-rabbit peroxidase-conjugated immunoglobulin (IgG), which was
diluted 1:10,000 in Tris-buffered saline (TBS). SpeB was detected using
an anti-SpeB mouse monoclonal antibody, diluted 1:25,000 in TBS,
followed by goat anti-mouse peroxidase-conjugated IgG (at 1:10,000
dilution). The blots were developed with the ECL reagent as described above.
SpeA- or SpeB-negative or -positive individual colonies derived from
the original isolate or from isolates that were recovered from the
infection chambers on various days postinfection were identified and
picked for further growth and analysis or for reinoculation into new
tissue chambers.
 |
RESULTS |
Effect of environmental factors on the induction of SpeA expression
in vivo.
In many pathogenic bacteria, environmental conditions,
including a change in incubation temperature, iron starvation, and the
relative levels of atmospheric O2 and
CO2, and other growth factors serve as signals
that potentiate the expression of virulence factors. In this study we
have attempted to induce the expression of SpeA by
speA-positive, SpeA-negative isolates in vitro by growing the bacteria under different conditions that have been previously reported to affect the expression of other virulence genes of GAS
(8, 10, 12, 31, 32, 49). Isolates were grown at
temperatures ranging from ambient temperature to 42°C or in different
media with and without various supplements including riboflavin, as
well as under iron deprivation conditions by adding ethylenediaminediacetic acid or nitrilotriacetic acid with or without
ferric citrate. GAS isolates were also subjected to growth in the
presence of different levels of CO2 (5 to 10%)
with shaking or static incubation. Isolates were also grown and
recovered at different phases of growth, including early, mid-, and
post-log phases. Many of these conditions affected the growth of the
bacteria; however, none induced SpeA expression (data not shown).
Accordingly, we tested whether expression of SpeA could be turned on in vivo.
Teflon tissue chamber infection model.
Implantation of the
micropore Teflon-FEP tissue chambers (Fig. 1) subcutaneously in mice
for 3 weeks resulted in the sealing of the chamber pores and the
accumulation of sterile straw-colored chamber fluid, which could be
sampled using a 25-gauge needle. Vascularized connective tissue
surrounded the chamber, and a white blood cell infiltrate consisting
primarily of neutrophils was detected in the recovered fluid. Seven
M1T1 GAS isolates and one M49 isolate were individually inoculated into
the connective tissue-sealed chambers (a minimum of five mice per
isolate per experiment). All M1T1 isolates harbored the speA
gene, and except for isolate 8004 none expressed the SpeA protein. M49
isolate NZ131 lacked the speA gene and served as a negative
control (Table 1). Isolate 8004 expressed
constitutive high levels of SpeA (Fig. 2)

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of SpeA, SpeB, and SpeF in partially purified
culture supernatants of GAS isolates prior to inoculation into tissue
chambers. The expression of SpeA, SpeB, and SpeF in culture
supernatants of the various isolates prior to in vivo inoculation into
the tissue chambers was determined by Western blotting using antibodies
to SpeA, SpeB, and SpeF as described in Materials and Methods.
|
|
The chambers were inoculated with 100 µl containing 1 × 105 to 5 × 105 CFU of
the various isolates, and growth rate was monitored by in vitro culture
of chamber fluid recovered on successive days postinfection. The growth
curve profiles for the various isolates were similar, and neither the
presence of the speA gene nor the expression of the SpeA
protein by the isolates prior to the infection had a significant effect
on the in vivo growth of the isolates (data not shown). To investigate
whether the inoculum size affects the growth of the bacteria in the
chambers, isolate 6050 was inoculated at levels ranging from 1 × 103 to 5 × 105 CFU
and growth kinetics in vivo were monitored. Regardless of the initial
inoculum size, a progressive and significant increase in the number of
CFU per milliliter was evident between day 1 and day 5, after which a
plateau was reached, i.e., between days 5 to 7, when a value of
~109 CFU/ml was reached (data not shown). When
a low inoculum was used (i.e., 103 CFU/chamber),
several mice cleared the infection; however, in those mice where
infection was established, the growth of the bacteria reached the same
level (CFU per milliliter) in the chamber on day 5 as in mice
inoculated with 104 or 105
CFU. Infection was more readily established in the majority of mice
receiving 105 CFU. Accordingly, for the remainder
of the study, chambers were inoculated with 100 µl containing
105 CFU of the GAS isolates.
Although neutrophils infiltrated the tissue-sealed chamber by
diapedesis, the bacteria, which cannot perform this function, remained
confined to the chambers. It is possible that a few bacteria were able
to penetrate the chambers; however, there was no sign of bacterial
dissemination because blood agar cultures of tissue homogenate from
liver, spleen, lung, and kidney or cultures of blood and peritoneal
fluid from infected animals failed to grow bacteria. Therefore, even if
a few bacteria escaped the chamber they appear to have been cleared by
the mouse innate immunity. In the few cases when the outside of the
chamber became clearly infected due to technical problems, the bacteria
disseminated and the mice died within 24 h. Despite evidence that
the bacteria remained confined in the tissue chambers and despite the
lack of detectable bacterial dissemination in the infected mice, there was clear evidence for a strong systemic inflammation in all mice examined. A mucoid pus surrounded the tissue chambers of infected animals, and significant increases in the sizes and weights of spleens
(threefold increases) were noted in infected animals by day 14 postinfection (data not shown). These changes were not seen in control
animals whose chambers were inoculated with PBS. Furthermore, injection
of 100 µl of sterile PBS into the tissue chambers caused no change in
the number of white blood cell infiltrates over a 21-day
infection course. By contrast, inoculation with 105 CFU of GAS strains induced an inflammatory
response and caused an approximately 100-fold increase in the number of
white blood cell infiltrates inside the chamber by day 7 (data not
shown). Together the data indicate that the sealing of the chamber with vascularized connective tissue allowed the diffusion of bacterial soluble products and infiltration of immune cells in and out of the chamber, while the bacterium itself remained confined
inside the chamber. This allowed sequential sampling of GAS isolates from the chamber on different days following infection in order to investigate possible changes in Spe expression in vivo.
Induction of SpeA expression in vivo.
The expression of SpeA,
SpeB, and SpeF was analyzed by Western blotting in the partially
purified culture supernatants prepared from the isolates on the day of
infection (day 0) as well as in chamber fluid aliquots, aspirated from
the chambers on various days postinfection. The production of SpeA,
SpeB, and SpeF in the culture supernatants of the GAS isolates prior to
inoculation into chambers varied for the different isolates. Prior to
infection, isolate 8004 expressed high levels of SpeA but did not
express SpeB or SpeF, whereas isolates 5459 and 5628 expressed neither SpeA nor SpeB but both expressed SpeF. M1T1 isolates 5448, 5449, 5836, and 6050 expressed SpeB but not SpeA. Isolate NZ131 (M49), which lacks
the speA gene, expressed SpeB. Therefore, prior to in vivo
inoculation, all M1T1 isolates except isolate 8004 expressed no
detectable amounts of SpeA protein even in the 20-fold-concentrated supernatants (Fig. 2).
By contrast, after in vivo inoculation of the SpeA-negative isolates
into the tissue chambers, low levels of expression of the SpeA protein
were detected in the aspirated chamber fluid recovered from most
infected animals on day 3 postinfection, and the amount of SpeA in the
chamber fluid gradually increased with time (Fig.
3A). Variation of SpeA expression and the
amount of SpeA produced in the chamber fluid among mice with respect to time was seen, but by day 7 the chamber fluid aspirated from all M1T1-infected animals showed evidence for SpeA expression (Fig. 3B).
Expression of SpeA persisted for the duration of the observation period
(14 to 21 days postinfection) (Fig. 3A). Expression of SpeA in chamber
fluids of animals infected with isolate 8004, which expressed high
levels of SpeA in vitro prior to infection, remained essentially
unchanged during the course of the infection, and, as expected, no SpeA
was detected in the chamber fluid of animals infected with isolate
NZ131, which lacks the speA gene (Fig. 3B).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
Temporal expression of SpeA in chamber fluid following
infection with speA+ SpeA GAS
isolates. Isolates that harbor the speA gene but that
express no detectable SpeA protein in vitro were inoculated into tissue
chambers of mice (105 CFU/100 µl/chamber). (A) On the
indicated days, 100 µl of chamber fluid was aspirated and analyzed
for SpeA expression by Western blotting as described in Materials and
Methods. Lanes 1 to 3 (counting from the left), standard rSpeA, SpeB,
and rSpeF (100 ng each); lanes 4 to 8, tissue chamber fluid
(TCF) aspirated on days 0 to 21 postinfection with isolate 5448 or isolate 6005. The same pattern of temporal induction of SpeA
expression was seen with the other speA+
SpeA M1T1 GAS isolates. (B) Expression of SpeA on day 7 postinfection with all isolates. A minimum of five mice per isolate per
time point were studied, and results shown are from a single
representative chamber fluid.
|
|
Stable expression of SpeA by GAS isolates recovered from the
chamber fluid.
To determine whether the induction of
speA gene expression after infection persists in vitro after
recovery of isolates from the infection chambers, representative
isolate 6050 was inoculated into chambers of mice and bacteria
recovered from the infected chambers on days 3, 7, 10, 14, and 21 postinoculation were grown in vitro. The production of SpeA and SpeB in
individual colonies as well as in the overnight culture supernatants
from the recovered bacteria in vitro was detected by colony lift assays
and by Western blotting, respectively. As shown in Fig.
4, the original 6050 colonies were all
SpeA negative and SpeB positive, whereas the majority of colonies
derived from 6050 bacteria, recovered 14 days postinfection, were all
SpeA positive and SpeB negative.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
Colony lift immunoblot of isolate 6050 colonies before
and after recovery from an infected-tissue chamber. Isolates were
recovered from chamber fluid aspirates obtained on day 7 or 14 postinfection, diluted, and plated on solid media to obtain individual
colonies. Colonies from the original and recovered isolates were
overlaid with nitrocellulose membranes, which were probed for SpeA
expression using anti-SpeA antibodies as described in Materials and
Methods. The blots shown are representative of a minimum of five
different experiments with blots performed on bacteria recovered on
different days.
|
|
In addition to the colony lift assay, bacteria recovered on various
days postinfection were grown in vitro for 21 passages and the
production of SpeA and SpeB was analyzed. Induction of SpeA expression
in vivo was temporally paralleled by decreased SpeB expression in
bacteria recovered on days 7 to 14 postinfection (Fig.
5). Bacteria recovered 3 days
postinfection reverted to the original SpeA-negative, SpeB-positive
phenotype. By contrast, bacteria recovered between days 7 and 14, which
had switched on the speA gene and which became SpeA positive
and SpeB negative, retained this phenotype for up to 21 passages.
Isolates recovered 21 days postinoculation were also SpeA positive and
SpeB negative and retained this phenotype upon successive passages;
however, at passage 15 they reverted back to the original SpeA-negative phenotype. As isolates recovered on day 21 postinfection reverted back
to the SpeA-negative phenotype, SpeB expression was regained.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Persistence of SpeA expression by isolates recovered
from the infection chambers. Mouse tissue chambers were inoculated with
isolate 6050 as detailed in the legend to Fig. 4. Bacteria were
recovered from chamber fluid aspirates obtained on days 3, 7, 10, and
21 postinfection and passaged in vitro for the indicated passage
numbers (passages 1 to 21). Partially purified culture supernatants
from the various passages were analyzed for SpeA and SpeB expression by
Western blotting as described in Materials and Methods.
|
|
The temporal inverse relation between SpeA and SpeB production raised
the possibility that SpeB, a cysteine protease, may be causing
proteolysis of SpeA. This possibly was unlikely because two other
isolates included in this study, isolates 5459 and 5628, expressed
neither SpeA nor SpeB prior to in vivo inoculation; however, both
isolates turned on speA gene expression following in vivo
inoculation into the chambers (Fig. 3B). Nonetheless, to further
address the possible effect of SpeB on the SpeA protein, several
original SpeA-negative, SpeB-positive isolates were grown in the
presence or in the absence of SpeB protease inhibitor E-64. Inhibition of cysteine protease activity had no effect on the original
SpeA-negative phenotype of these isolates (data not shown). Together,
the data indicate that the lack of expression of SpeA by the original
M1T1 isolates and its induction in vivo are not due to
downregulation of SpeB expression but rather to a switch off of
speA.
Induction of SpeA expression in vivo is not due to selective growth
of SpeA-positive colonies.
The possibility that the original 6050 inoculum contained rare SpeA-positive colonies that could have had a
selective growth advantage in vivo was addressed. Isolate 6050 was
inoculated into the chambers, and the bacteria recovered from the
chamber fluids on day 5 postinfection, which contained a mixture of
SpeA-positive and a few SpeA-negative colonies, were analyzed by the
colony lift blot assay for SpeA expression. Two colonies that were
clearly either SpeA positive or SpeA negative were selected and grown in vitro separately. The 6050 SpeA-positive and 6050 SpeA-negative colonies were individually reinoculated into mouse chambers, and expression of SpeA and SpeB was monitored on various days postinfection (Fig. 6). The bacteria derived from
chambers inoculated with the SpeA-negative colony switched on SpeA
expression by day 5 postinfection, and those derived from the
SpeA-positive colony continued to express SpeA (Fig. 6). Together
the data indicate that the expression of SpeA in vivo was not
attributed to a selective growth advantage of rare SpeA-positive
isolates in the original inoculum; rather, speA gene
expression is indeed turned on in vivo.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
In vivo expression of SpeA by SpeA-positive and
SpeA-negative clones derived from isolate 6050 recovered 5 days
postinfection from the tissue chamber. Isolate 6050 was inoculated into
a tissue chamber and recovered on day 5 from the chamber fluid. The
bacteria were diluted and spread on blood agar plates to obtain
individual colonies. The colonies were analyzed for SpeA expression by
the colony lift immunoblot assay described in Materials and Methods and
illustrated in Fig. 5. SpeA-positive and SpeA-negative colonies were
identified and picked for further growth. The bacteria derived from the
SpeA-positive and SpeA-negative colonies were grown in vitro, and the
supernatants were analyzed for SpeA and SpeB expression. In addition,
the bacteria derived from the SpeA-positive and SpeA-negative colonies
were reinoculated into tissue chambers of mice and then recovered on
days 3, 5, and 15. Production of SpeA and SpeB by the recovered
bacteria, which were originally derived from the SpeA-positive and
SpeA-negative colonies, was analyzed by Western blotting as detailed in
Materials and Methods.
|
|
The possibility that the induction of the speA gene in the
chamber was due to a quorum-sensing mechanism (i.e., interbacterial communication signal as a result of growth phase regulation) related to
the inability of the bacteria to leave the chamber was addressed. The
bacteria were grown in vitro under conditions that simulate the
"crowded" condition inside the tissue cage (initial inoculum, 105 to
106 CFU/ml). In one set,
samples of the growing culture were tested for SpeA and SpeB expression
on days 1, 3, 4, 5, and 7 and were subcultured in 10 ml of fresh medium
to mimic the sampling protocol used with the mouse chamber model.
Another set was established as a continuous culture; the culture was
centrifuged daily, the supernatant was removed for analysis, and the
pellet was regrown in the same volume of fresh medium according to the
above schedule. None of the above conditions induced SpeA expression
(data not shown). Growing the bacteria in human plasma also failed to
induce SpeA expression.
 |
DISCUSSION |
Despite the many elegant studies investigating regulatory
mechanisms controlling the transcription and/or posttranslational modification of key streptococcal virulence factors such as SpeB, little is known about the regulation of other Spes, including SpeA.
This toxin is considered to be an important virulence component of GAS
because of its potent superantigenic properties (19, 21).
Much interest has focused on SpeA because the majority of invasive GAS
infections since the 1980s have been caused by highly related M1T1
strains that harbor the speA gene (7, 24, 46).
In addition, low levels of antibodies to SpeA, as well as to other
Spes, in serum have been associated with increased risk of
invasive disease (3, 26, 39, 45). However, the role of
SpeA in STSS has been questioned in part because in vitro toxin
production by clinical isolates is highly variable (7, 10, 33,
47). A number of studies, including our own, have noted that 20 to 50% of speA-positive clinical M1 isolates do not express
the SpeA protein (7, 10, 17, 34, 47). The question of
whether SpeA is expressed in vivo but not in vitro or vice versa has
not been directly answered.
In this study we investigated the in vitro and in vivo expression of
SpeA by clonal M1T1 isolates recovered from invasive GAS cases.
Attempts to induce superantigen, SpeA, expression in vitro in six
representative speA+
SpeA
isolates by varying culture
conditions (e.g., temperature, pH, CO2,
O2, etc.) or the composition of the growth media
failed. Inasmuch as several of our clinical isolates derived
from the clonal M1T1 strain were either producing no, low, or high
levels of SpeA when originally isolated from the patients
(7) and these isolates retained the original Spe phenotype
upon continuous passage in culture, we hypothesized that in vivo
environmental signals may stably turn on or off expression of specific
Spe genes. Here we provided evidence that SpeA expression can be stably
turned on in vivo, while SpeB expression is turned off. Thus, the data support the hypothesis and open the door for future investigations into
the underlying molecular mechanism responsible for this phenomenon.
To monitor the in vivo expression of Spes over a relatively long
period of time, it was necessary to develop a nonlethal model of
infection. A mouse chamber model of localized GAS infection was,
therefore, developed to investigate the effect of host-pathogen interaction on the expression of bacterial virulence genes. Several murine, rabbit, and monkey models of streptococcus infections have been
developed, and these have generated important information regarding the
pathogenesis of GAS and the role of various virulence factors in the in
vivo infection (5, 29, 35, 43). The micropore Teflon
chamber used here is a modification of the steel cage model that was
developed by Nordstrand et al. (35). The vascularized
connective tissue-sealed Teflon micropore chamber allows sequential
sampling of tissue fluid containing the bacteria at different times
postinfection from the same mouse. This feature reduces the variability
among animals. Thus, our Teflon tissue chamber model combines the
favorable properties of the air pouch model (5) and the
innovation of the steel tissue chamber model developed by Nordstrand et
al. (35). Further, because the bacteria remain confined in
the chamber, the mice survive for a prolonged period of time, thereby
allowing long-term monitoring of the in vivo environmental effects on
the kinetics of expression of bacterial virulence genes.
As the expression of SpeA increased following in vivo inoculation,
expression of SpeB was temporally downregulated. To our knowledge, the
production of SpeA locally or systemically under in vivo conditions by
strains which had failed to produce detectable levels of the protein in
vitro has not been previously described. Although the kinetics of
speA gene induction varied slightly for different isolates
and in different mice, all speA-positive, SpeA-negative isolates expressed high levels of SpeA by day 7 postinfection. A
bacterial environmental monitoring system which operates in the in vivo
hostile environment may have triggered the maximal expression of the
speA gene. Recent studies by Broudy et al. (6) showed that GAS cocultured with a human pharyngeal cell line
upregulated SpeC expression within 3 h of coincubation. In our
model, induction occurred after 3 to 5 days in the chamber, which
contained high numbers of leukocytic infiltrate. The difference in the
kinetics of Spe expression between the two systems could be due
to differences in speA and speC regulation.
Alternatively, the pharyngeal cell line used in the study by Broudy et
al. may have acquired a constitutive signal as a result of cellular
transformation that induces Spe expression, whereas in our model
expression of this signal may require 3 to 5 days and thus represents
actual in vivo kinetics. Future studies will explore the difference in
kinetics of SpeA expression between the ex vivo and in vivo systems and
will aim to identify the nature of the signal derived from the host.
Isolates recovered from the tissue chamber starting on day 7 and up to
day 14 continued to express SpeA in vitro after their removal from the
in vivo environment, and serial passages in vitro failed to turn off
the speA gene. This suggests that an environmental or host
signal in vivo has caused the gene to be irreversibly turned on. The
nature of this signal is currently under investigation, but it is
noteworthy that several isolates in our series of over 100 clonal M1T1
isolates expressed constitutive high levels of SpeA in vitro
immediately after recovery from the patients and that this expression
was not attenuated or turned off by serial passages in vitro. Isolate
8004 studied here is representative of isolates expressing high levels
of SpeA; for this isolate speA gene expression was
constitutive both in vitro and in vivo and speB gene
expression was turned off. Therefore, it appears that events
occurring both in humans and mice can permanently turn on the
speA gene. However, this signal may be different in
different individuals inasmuch as 40% of clonal M1T1 isolates
recovered from our patients had not switched on the SpeA gene.
The advantage of turning the speA gene on or off is not
clear. Although production of SpeA in vivo may influence the severity of infection, sustained production of this toxin can lead to the development of antibodies that can neutralize its superantigenic activity and protect the host against subsequent infections. Indeed, vaccination with SpeA has been shown to confer protection in animal models of STSS and necrotizing fasciitis (44), and low
levels of anti-SpeA neutralizing antibodies have been reported in sera from invasive GAS infection cases (3, 26, 27, 39, 45) as
well as in various intravenous immunoglobulin preparations (36, 37). Interestingly, a recent report by Sriskandan et al. (44) showed that, in a murine model of peritoneal
infection, speA-negative mutants were more virulent
than the isogenic speA-positive wild-type strain.
Increased mortality was seen after intravenous injection of the mutant
strain. Furthermore, when the mutant strain was injected
intramuscularly, it led to increased bacteremia and a reduction in
neutrophil sequestration at the site of primary muscle infection.
Therefore, it is possible that, under certain conditions, the bacteria
may need to turn off certain virulence genes; while important to the
pathogen, the encoded toxins may compromise the ability of the
bacteria to continue to survive in the host. Support for this
notion is found in a recent study by Kansal et al.
(18), which demonstrated that a lack of SpeB expression is
associated with increased severity of invasive GAS disease. Future work
should reveal the role of the differential regulation of Spe gene
expression in pathogenesis.
In summary, the current Teflon tissue chamber model allowed us to
establish a streptococcal infection leading to induction of the
speA gene in vivo. This model, which allows repeated
sampling from the infection focus to determine the temporal expression of Spe genes, will enable us to investigate the in vivo signals required for turning on the speA gene and turning off the
speB gene. This information will help us better understand
the role of host-pathogen interactions in regulating the expression of streptococcal virulence factors.
 |
ACKNOWLEDGMENTS |
This work was supported by grants AI40198 from the National
Institutes of Health NIAID (M.K.) and by a Merit Review Award from the
U.S. Veterans Affairs (M.K.), as well as by funds from the joint
Veterans Affairs/Department of Defense Research Initiative (M.K.).
We thank James Musser for the kind gift of anti-SpeB antibodies and
Andy Lundberg for his surgical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Tennessee, Memphis, 956 Court Ave., Suite A-202, Memphis, TN 38163. Phone: (901) 448-7247. Fax: (901) 448-7208. E-mail:
mkotb{at}utmem.edu.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Ashbaugh, C. D.,
S. Alberti, and M. R. Wessels.
1998.
Molecular analysis of the capsule gene region of group A Streptococcus: the hasAB genes are sufficient for capsule expression.
J. Bacteriol.
180:4955-4959[Abstract/Free Full Text].
|
| 2.
|
Ashbaugh, C. D.,
H. B. Warren,
V. J. Carey, and M. R. Wessels.
1998.
Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection.
J. Clin. Investig.
102:550-560[Medline].
|
| 3.
|
Basma, H.,
A. Norrby-Teglund,
Y. Guedez,
A. McGeer,
D. E. Low,
O. El-Ahmedy,
B. Schwartz, and M. Kotb.
1999.
Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity.
Infect. Immun.
67:1871-1877[Abstract/Free Full Text].
|
| 4.
|
Bernish, B., and I. van de Rijn.
1999.
Characterization of a two-component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production.
J. Biol. Chem.
274:4786-4793[Abstract/Free Full Text].
|
| 5.
|
Boyle, M. D.,
R. Raeder,
A. Flosdorff, and A. Podbielski.
1998.
Role of emm and mrp genes in the virulence of group A streptococcal isolate 64/14 in a mouse model of skin infection.
J. Infect. Dis.
177:991-997[Medline].
|
| 6.
|
Broudy, T. B.,
V. Pancholi, and V. A. Fischetti.
2001.
Induction of lysogenic bacteriophage and phage-associated toxin from group A streptococci during coculture with human pharyngeal cells.
Infect. Immun.
69:1440-1443[Abstract/Free Full Text].
|
| 7.
|
Chatellier, S.,
N. Ihendyane,
R. G. Kansal,
F. Khambaty,
H. Basma,
A. Norrby-Teglund,
D. E. Low,
A. McGeer, and M. Kotb.
2000.
Genetic relatedness and superantigen expression of M type 1 group A streptococcal isolates from severe and nonsevere invasive disease.
Infect. Immun.
68:3523-3534[Abstract/Free Full Text].
|
| 8.
|
Chaussee, M. S.,
J. Liu,
D. L. Stevens, and J. J. Ferretti.
1997.
Effects of environmental factors on streptococcal erythrogenic toxin A (SPE A) production by Streptococcus pyogenes.
Adv. Exp. Med. Biol.
418:551-554[Medline].
|
| 9.
|
Chaussee, M. S.,
J. Liu,
D. L. Stevens, and J. J. Ferretti.
1996.
Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections.
J. Infect. Dis.
173:901-908[Medline].
|
| 10.
|
Chaussee, M. S.,
E. R. Phillips, and J. J. Ferretti.
1997.
Temporal production of streptococcal erythrogenic toxin B (streptococcal cysteine proteinase) in response to nutrient depletion.
Infect. Immun.
65:1956-1959[Abstract].
|
| 11.
|
Cleary, P. P.,
E. L. Kaplan,
J. P. Handley,
A. Wlazlo,
M. H. Kim,
A. R. Hauser, and P. M. Schlievert.
1992.
Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s.
Lancet
339:518-521[CrossRef][Medline].
|
| 12.
|
Cleary, P. P.,
L. McLandsborough,
L. Ikeda,
D. Cue,
J. Krawczak, and H. Lam.
1998.
High-frequency intracellular infection and erythrogenic toxin A expression undergo phase variation in M1 group A streptococci.
Mol. Microbiol.
28:157-167[CrossRef][Medline].
|
| 13.
|
Cunningham, M. W.
2000.
Pathogenesis of group A streptococcal infections.
Clin. Microbiol. Rev.
13:470-511[Abstract/Free Full Text].
|
| 14.
|
Federle, M. J.,
K. S. McIver, and J. R. Scott.
1999.
A response regulator that represses transcription of several virulence operons in the group A streptococcus.
J. Bacteriol.
181:3649-3657[Abstract/Free Full Text].
|
| 15.
|
Ferrieri, P.
1991.
Microbiological features of current virulent strains of group A streptococci.
Pediatr. Infect. Dis. J.
10(Suppl.):S20-S24[Medline].
|
| 16.
|
Heath, A.,
V. J. DiRita,
N. L. Barg, and N. C. Engleberg.
1999.
A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B.
Infect. Immun.
67:5298-5305[Abstract/Free Full Text].
|
| 17.
|
Holm, S. E.,
A. Norrby,
A. M. Bergholm, and M. Norgren.
1992.
Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988 to 1989.
J. Infect. Dis.
166:31-37[Medline].
|
| 18.
|
Kansal, R. G.,
A. McGeer,
D. E. Low,
A. Norrby-Teglund, and M. Kotb.
2000.
Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases.
Infect. Immun.
68:6362-6369[Abstract/Free Full Text].
|
| 19.
|
Kotb, M.
1995.
Bacterial pyrogenic exotoxins as superantigens.
Clin. Microbiol. Rev.
8:411-426[Abstract].
|
| 20.
|
Kotb, M.
1992.
Role of superantigens in the pathogenesis of infectious diseases and their sequelae.
Curr. Opin. Infect. Dis.
5:364-374[CrossRef].
|
| 21.
|
Kotb, M.
1998.
Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity.
Curr. Opin. Microbiol.
1:56-65[CrossRef][Medline].
|
| 22.
|
Levin, J. C., and M. R. Wessels.
1998.
Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A streptococcus.
Mol. Microbiol.
30:209-219[CrossRef][Medline].
|
| 23.
|
Li, Z.,
D. D. Sledjeski,
B. Kreikemeyer,
A. Podbielski, and M. D. Boyle.
1999.
Identification of pel, a Streptococcus pyogenes locus that affects both surface and secreted proteins.
J. Bacteriol.
181:6019-6027[Abstract/Free Full Text].
|
| 24.
|
Low, D. E.,
B. Schwartz, and A. McGeer.
1998.
The reemergence of severe group A streptococcal disease: an evolutionary perspective, p. 93-123.
In
Emerging infections, vol. 1. ASM Press, Washington, D.C.
|
| 25.
|
Lyon, W. R.,
C. M. Gibson, and M. G. Caparon.
1998.
A role for trigger factor and an rgg-like regulator in the transcription, secretion and processing of the cysteine proteinase of Streptococcus pyogenes.
EMBO J.
17:6263-6275[CrossRef][Medline].
|
| 26.
|
Mascini, E. M.,
M. M. Hazenberg,
A. van Dalen,
L. A. Verhoef-Verhage,
N. J. van Leeuwen,
J. Verhoef, and H. van Dijk.
1997.
Invasive group A streptococcal disease. Association with a lack of anti-exotoxin antibodies.
Adv. Exp. Med. Biol.
418:921-922[Medline].
|
| 27.
|
Mascini, E. M.,
M. Jansze,
J. F. Schellekens,
J. M. Musser,
J. A. Faber,
L. A. Verhoef-Verhage,
L. Schouls,
W. J. van Leeuwen,
J. Verhoef, and H. van Dijk.
2000.
Invasive group A streptococcal disease in The Netherlands: evidence for a protective role of anti-exotoxin A antibodies.
J. Infect. Dis.
181:631-638[CrossRef][Medline].
|
| 28.
|
Mascini, E. M.,
M. Jansze,
L. M. Schouls,
A. C. Fluit,
J. Verhoef, and H. van Dijk.
1999.
Invasive and noninvasive group A streptococcal isolates with different speA alleles in The Netherlands: genetic relatedness and production of pyrogenic exotoxins A and B.
J. Clin. Microbiol.
37:3469-3474[Abstract/Free Full Text].
|
| 29.
|
McCormick, J. K.,
T. J. Tripp,
S. B. Olmsted,
Y. V. Matsuka,
P. J. Gahr,
D. H. Ohlendorf, and P. M. Schlievert.
2000.
Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome.
J. Immunol.
165:2306-2312[Abstract/Free Full Text].
|
| 30.
|
McIver, K. S.,
A. S. Heath,
B. D. Green, and J. R. Scott.
1995.
Specific binding of the activator Mga to promoter sequences of the emm and scpA genes in the group A streptococcus.
J. Bacteriol.
177:6619-6624[Abstract/Free Full Text].
|
| 31.
|
McIver, K. S., and J. R. Scott.
1997.
Role of mga in growth phase regulation of virulence genes of the group A streptococcus.
J. Bacteriol.
179:5178-5187[Abstract/Free Full Text].
|
| 32.
|
McIver, K. S.,
A. S. Thurman, and J. R. Scott.
1999.
Regulation of mga transcription in the group A streptococcus: specific binding of mga within its own promoter and evidence for a negative regulator.
J. Bacteriol.
181:5373-5383[Abstract/Free Full Text].
|
| 33.
|
Musser, J. M.,
A. R. Hauser,
M. H. Kim,
P. M. Schlievert,
K. Nelson, and R. K. Selander.
1991.
Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression.
Proc. Natl. Acad. Sci. USA
88:2668-2672[Abstract/Free Full Text].
|
| 34.
|
Nakashima, K.,
S. Ichiyama,
Y. Iinuma,
Y. Hasegawa,
M. Ohta,
K. Ooe,
Y. Shimizu,
H. Igarashi,
T. Murai, and K. Shimokata.
1997.
A clinical and bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints.
Clin. Infect. Dis.
25:260-266[Medline].
|
| 35.
|
Nordstrand, A.,
M. Norgren, and S. E. Holm.
1996.
An experimental model for acute poststreptococcal glomerulonephritis in mice.
APMIS
104:805-816[Medline].
|
| 36.
|
Norrby-Teglund, A.,
H. Basma,
J. Andersson,
A. McGeer,
D. E. Low, and M. Kotb.
1998.
Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy.
Clin. Infect. Dis.
26:631-638[Medline].
|
| 37.
|
Norrby-Teglund, A.,
N. Ihendyane,
R. Kansal,
H. Basma,
M. Kotb,
J. Andersson, and L. Hammarstrom.
2000.
Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens.
Clin. Infect. Dis.
31:1175-1182[CrossRef][Medline].
|
| 38.
|
Norrby-Teglund, A., and M. Kotb.
2000.
Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections.
J. Med. Microbiol.
49:849-852[Medline].
|
| 39.
|
Norrby-Teglund, A.,
K. Pauksens,
S. E. Holm, and M. Norgren.
1994.
Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease.
J. Infect. Dis.
170:585-591[Medline].
|
| 40.
|
Okada, N.,
R. T. Geist, and M. G. Caparon.
1993.
Positive transcriptional control of mry regulates virulence in the group A streptococcus.
Mol. Microbiol.
7:893-903[CrossRef][Medline].
|
| 41.
|
Podbielski, A.,
A. Flosdorff, and J. Weber-Heynemann.
1995.
The group A streptococcal virR49 gene controls expression of four structural vir regulon genes.
Infect. Immun.
63:9-20[Abstract].
|
| 42.
|
Podbielski, A., and B. A. Leonard.
1998.
The group A streptococcal dipeptide permease (Dpp) is involved in the uptake of essential amino acids and affects the expression of cysteine protease.
Mol. Microbiol.
28:1323-1334[CrossRef][Medline].
|
| 43.
|
Roggiani, M.,
J. A. Stoehr,
S. B. Olmsted,
Y. V. Matsuka,
S. Pillai,
D. H. Ohlendorf, and P. M. Schlievert.
2000.
Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome.
Infect. Immun.
68:5011-5017[Abstract/Free Full Text].
|
| 44.
|
Sriskandan, S.,
M. Unnikrishnan,
T. Krausz, and J. Cohen.
1999.
Molecular analysis of the role of streptococcal pyrogenic exotoxin A (SPEA) in invasive soft-tissue infection resulting from Streptococcus pyogenes.
Mol. Microbiol.
33:778-790[CrossRef][Medline].
|
| 45.
|
Stevens, D. L.
1995.
Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment.
Emerg. Infect. Dis.
1:69-78[Medline].
|
| 46.
|
Stevens, D. L.
1997.
The toxins of group A streptococcus, the flesh eating bacteria.
Immunol. Investig.
26:129-150[Medline].
|
| 47.
|
Talkington, D.,
B. Schwartz,
C. Black,
J. Todd,
J. Elliott,
R. Breiman, and R. Facklam.
1993.
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome.
Infect. Immun.
61:3369-3374[Abstract/Free Full Text].
|
| 48.
|
Tomai, M.,
P. M. Schlievert, and M. Kotb.
1992.
Distinct T-cell receptor V gene usage by human T lymphocytes stimulated with the streptococcal pyrogenic exotoxins and M protein.
Infect. Immun.
60:701-705[Abstract/Free Full Text].
|
| 49.
|
Xu, S., and C. M. Collins.
1996.
Temperature regulation of the streptococcal pyrogenic exotoxin A-encoding gene (speA).
Infect. Immun.
64:5399-5402[Abstract].
|
Infection and Immunity, August 2001, p. 4988-4995, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.4988-4995.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nooh, M. M., Aziz, R. K., Kotb, M., Eroshkin, A., Chuang, W.-J., Proft, T., Kansal, R.
(2006). Streptococcal Mitogenic Exotoxin, SmeZ, Is the Most Susceptible M1T1 Streptococcal Superantigen to Degradation by the Streptococcal Cysteine Protease, SpeB. J. Biol. Chem.
281: 35281-35288
[Abstract]
[Full Text]
-
Ma, Y., Bryant, A. E., Salmi, D. B., Hayes-Schroer, S. M., McIndoo, E., Aldape, M. J., Stevens, D. L.
(2006). Identification and Characterization of Bicistronic speB and prsA Gene Expression in the Group A Streptococcus. J. Bacteriol.
188: 7626-7634
[Abstract]
[Full Text]
-
Graham, M. R., Virtaneva, K., Porcella, S. F., Gardner, D. J., Long, R. D., Welty, D. M., Barry, W. T., Johnson, C. A., Parkins, L. D., Wright, F. A., Musser, J. M.
(2006). Analysis of the Transcriptome of Group A Streptococcus in Mouse Soft Tissue Infection. Am. J. Pathol.
169: 927-942
[Abstract]
[Full Text]
-
Cole, J. N., McArthur, J. D., McKay, F. C., Sanderson-Smith, M. L., Cork, A. J., Ranson, M., Rohde, M., Itzek, A., Sun, H., Ginsburg, D., Kotb, M., Nizet, V., Chhatwal, G. S., Walker, M. J.
(2006). Trigger for group A streptococcal M1T1 invasive disease. FASEB J.
20: 1745-1747
[Abstract]
[Full Text]
-
Hasty, D. L., Meron-Sudai, S., Cox, K. H., Nagorna, T., Ruiz-Bustos, E., Losi, E., Courtney, H. S., Mahrous, E. A., Lee, R., Ofek, I.
(2006). Monocyte and Macrophage Activation by Lipoteichoic Acid Is Independent of Alanine and Is Potentiated by Hemoglobin. J. Immunol.
176: 5567-5576
[Abstract]
[Full Text]
-
Graham, M. R., Virtaneva, K., Porcella, S. F., Barry, W. T., Gowen, B. B., Johnson, C. R., Wright, F. A., Musser, J. M.
(2005). Group A Streptococcus Transcriptome Dynamics during Growth in Human Blood Reveals Bacterial Adaptive and Survival Strategies. Am. J. Pathol.
166: 455-465
[Abstract]
[Full Text]
-
Brussow, H., Canchaya, C., Hardt, W.-D.
(2004). Phages and the Evolution of Bacterial Pathogens: from Genomic Rearrangements to Lysogenic Conversion. Microbiol. Mol. Biol. Rev.
68: 560-602
[Abstract]
[Full Text]
-
Canchaya, C., Proux, C., Fournous, G., Bruttin, A., Brussow, H.
(2003). Prophage Genomics. Microbiol. Mol. Biol. Rev.
67: 238-276
[Abstract]
[Full Text]
-
Chen, C.-Y., Luo, S.-C., Kuo, C.-F., Lin, Y.-S., Wu, J.-J., Lin, M. T., Liu, C.-C., Jeng, W.-Y., Chuang, W.-J.
(2003). Maturation Processing and Characterization of Streptopain. J. Biol. Chem.
278: 17336-17343
[Abstract]
[Full Text]